Ciprofloxacin
A broad-spectrum fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication. It is used for a wide range of infections including urinary tract infections, respiratory infections, typhoid fever, and anthrax prophylaxis. Tendon rupture, peripheral neuropathy, and prolongation of the QT interval are important safety concerns.
Peso molecular
331,3460 g/mol
LogP
-1,10
TPSA
72,90 Ų
Regla de cinco de Lipinski
Cumple
Áreas terapéuticas
Clases de fármacos
Mecanismo de acción
Inhibits bacterial DNA gyrase and topoisomerase IV.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits bacterial DNA gyrase and topoisomerase IV.
Estructura 2D
Cite this structure
Embed this structure
SMILES
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O
InChI
InChI=1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)
Molecular Formula
C17H18FN3O3
HBD / HBA
2 / 7
Enlaces Rotables
3
Átomos Pesados
24
Ciprofloxacin and ondansetron both prolong the QT interval; combined use raises the risk of torsades de pointes and sudden cardiac death.
Ciprofloxacin and quetiapine both prolong the QT interval and ciprofloxacin also increases quetiapine exposure via CYP3A4 inhibition.
Ciprofloxacin can reduce levothyroxine absorption through complex formation and potential effects on gut motility and transport, risking under-replacement in hypothyroid patients on long courses.
Ciprofloxacin consistently enhances warfarin's anticoagulant effect, raising INR and increasing the risk of bleeding complications.
Both azithromycin and ciprofloxacin prolong the QT interval; concurrent or overlapping use significantly increases torsades de pointes risk.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
A broad-spectrum fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication. It is used for a wide range of infections including urinary tract infections, respiratory infections, typhoid fever, and anthrax prophylaxis. Tendon rupture, peripheral neuropathy, and prolongation of the QT interval are important safety concerns.
Inhibits bacterial DNA gyrase and topoisomerase IV.
Key pharmacokinetic parameters for Ciprofloxacin: Half-life: 4 hours.
Yes, Ciprofloxacin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
Same Drug Class
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL8. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 2764. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ciprofloxacin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ciprofloxacin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ciprofloxacin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ciprofloxacin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ciprofloxacin"></drugfyi-drug>